For more than 20 years, our teams have worked to combat this zoonotic disease that threatens the health of dogs and humans alike. In 2024, we continue to work to bring diagnostic, prevention and treatment solutions to veterinarians and dog owners in endemic areas. Our latest stop is France, which will host the Animal Leishmaniosis International Veterinary Event in Nice in April.

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

As in other parts of the world, around 10%¹ of dogs in Asia suffer from atopic dermatitis. Since 2022, our teams have been stepping up their efforts to develop our global DailyDerma program in the region. The goal? To better help Asian veterinarians optimize their dermatology practices and improve the management of skin diseases, especially complex atopic dermatitis. 

●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability¹ at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability¹ expected to rise by 0,5 point
 

One year after the launch of Suigen Rota Coli, our teams in France and Germany are now offering a second vaccine for swine, Suigen APP 2,9,11. This new vaccine complements our solutions for the prevention of major swine diseases, helping farmers to better control the health of their farms.

Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Virbac announces the appointment of Olivier Charmeil as a new member of the board of directors with effect from December 21, 2023. He replaces Olivier Bohuon, permanent representative of OJB Conseil, within the board of directors and the appointments and compensation committee. 

Our range of dermatological (AKI) and hygiene (Allerderm) shampoos has been redesigned to limit ecological impact and simplify use for pet owners. The new packaging is now made from recycled plastic, while the innovative formulations, which have been constantly improved over the last few decades, remain unchanged.

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

Discover the video of Sébastien Huron's wishes to all Virbac teams worldwide.

Available in five major Chinese cities since last October, our Veterinary HPM^® physiological foods are the only ones in the country to be distributed exclusively in veterinary clinics. This is a novel approach in the region, in line with our medical and scientific approach to animal nutrition. 

Because we are all part of the same ecosystem, parasite control is a necessity which must be carried out while preserving the delicate balance between the health of animals, humans and their environment. With “Let's do it smart”, we provide veterinarians with the tools they need to tailor the solution to the animal's specific needs, thus contributing to a more reasoned use of parasiticides. 

A new filling line has been installed in Carros, marking the beginning of the transformation of our production system.

At the end of October, the French Customs Department awarded our Group the status of Authorized Economic Operator (AEO): a European customs seal of approval, recognized on the international scene.

On October 17, Virbac Uruguay celebrated 10 years of commitment to animal health in Montevideo. On this occasion, the foundation stone for our new viral antigen plant was laid in the presence of the President of the Republic of Uruguay. 

On November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Revenue growth at the end of September at +2.8% at constant exchange rates and scope thanks to a strong activity rebound in the third quarter (+7.8% at constant exchange rates and scope).

On October 11, 2023, the U.S. Food and drug administration (FDA) approved our solution for the treatment of Giardia duodenalis infections in dogs.

A study published in September 2023 has scientifically demonstrated that Vet Aquadent^® FR3SH^™ is an effective option to help maintain dogs' oral health after professional dental cleaning.

Virbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

In France and around the world, the medicalization of cats continues to progress, helping to increase their life expectancy. Two major pathologies affect these aging cats: chronic kidney disease and osteoarthritis. Specially adapted nutrition can help. That's why we're launching VETERINARY HPM^® Kidney & Joint in Europe in September. This new nutrition program enables the combined and gradual management of chronic kidney disease and osteoarthritis, thus improving the animal's quality of life. 

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

In June 2023, Virbac New Zealand celebrated 30 years of its commitment to animal health in Aotearoa New Zealand. All employees gathered together to mark this amazing achievement and look back on these past three decades.

Revenue up about 2% during the second quarter and stable at the end of June despite two unfavorable one-off effects throughout the semester

Last May, Virbac Japan employees gathered to celebrate the subsidiary's 30 years of commitment to animal health.

Virbac reassesses its 2023 growth and Adjusted EBIT¹ forecast